| Drug Name |
Nivolumab |
| Drug ID |
BADD_D01581 |
| Description |
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).[L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability.[A35203] It was developed by Bristol Myers Squibb.[L12129]
Nivolumab was granted FDA approval on 22 December 2014.[L12129] |
| Indications and Usage |
Nivolumab is indicated for the treatment of unresectable or metastatic melanoma for patients who no longer respond to treatment with other drugs. It is intended for use in patients who have been previously treated with ipilimumab and is used for melanoma patients after treatment with ipilimumab and a BRAF inhibitor in patients whose tumors express BRAF V600 gene mutations. Historically there have been very few effective treatments for advanced melanoma, which is why this product was approved under an FDA accelerated program to allow earlier patient access. |
| Marketing Status |
Prescription |
| ATC Code |
L01FF01 |
| DrugBank ID |
DB09035
|
| KEGG ID |
D10316
|
| MeSH ID |
D000077594
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
0952-3772; 0003-3734; 71124-0002; 68806-3772; 0003-3756; 70409-7125; 0003-3774; 0003-3772 |
| Synonyms |
Nivolumab | Opdivo | ONO-4538 | ONO 4538 | ONO4538 | MDX-1106 | MDX 1106 | MDX1106 | BMS-936558 | BMS 936558 | BMS936558 |
